News

AI Therapeutics‘ experimental therapy AIT-101 led to reductions in levels of toxic proteins in people with amyotrophic lateral sclerosis (ALS) associated with mutations in the C9ORF72 gene, according to data from a clinical trial. The Phase 2a clinical trial also met its main goals of showing that AIT-101…

Aural Analytics‘ speech analytics software app for amyotrophic lateral sclerosis (ALS), intended for use by researchers and doctors working in the disease, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The designation is meant to speed the development and review of…

An expanded access program for the experimental treatment SLS-005 has dosed its first participant, according to Seelos Therapeutics, the therapy’s developer. The expanded access program, or EAP, is an open-label study allowing access to SLS-005 for people with amyotrophic lateral sclerosis (ALS) who are…

AB Science has submitted its response to the European Medicines Agency (EMA), part of an ongoing review process aiming for the conditional approval of masitinib as an add-on oral therapy for amyotrophic lateral sclerosis (ALS). The Committee for Medicinal Products for Human Use (CHMP), an arm…

There are currently up to 18,000 people living with amyotrophic lateral sclerosis (ALS) in the U.S., with national costs likely to reach $1.02 billion each year, a study has found. Researchers also observed that men, white people, and veterans appear more likely to develop the disease. “However, large-scale, population-based…

TDP-43, a protein that is known to have toxic effects in amyotrophic lateral sclerosis (ALS), is able to interact with RNA molecules carrying a chemical modification called m6A, and this chemical modification is increased in ALS nerve cells, a new study shows. The findings add to a growing body…

NeuroSense Therapeutics has joined researchers at Massachusetts General Hospital to study the impact of its investigational therapy PrimeC on key amyotrophic lateral sclerosis (ALS) processes. The collaboration will the headed by Ghazaleh Sadri-Vakili, director of the Neuroepigenetics laboratory at the MassGeneral Institute for Neurodegenerative Disease. Using a new…

The ALS Society of Canada (ALS Canada) and Brain Canada are collaboratively investing CA$1.4 million (about $1.1M US) in nine grants for studies ranging from the development of new treatments for amyotrophic lateral sclerosis (ALS) to finding ways to predict disease progression. The ALS Canada Discovery…

Cytokinetics announced that it is stopping COURAGE-ALS, a Phase 3 trial investigating oral reldesemtiv in treating people with amyotrophic lateral sclerosis (ALS), due to a lack of efficacy compared with a placebo. In a review of unblinded interim trial findings at a second planned data monitoring committee meeting,…

A Phase 3b study evaluating the long-term safety and effectiveness of two dosing regimens of Radicava ORS (edaravone) — an approved oral formulation of the medicine — in people with amyotrophic lateral sclerosis (ALS) is now fully enrolled. The study was designed to fulfill a post-marketing commitment that…